Sign In
Buy NEO
$10.14
+0.0200 (+0.198%)
At Close: Jun 03, 2026
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
11:16am, Friday, 01'st Oct 2021
Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar with the matter. Related: Precision O
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
04:05pm, Wednesday, 01'st Sep 2021
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today ann
NeoGenomics, Inc. (NEO) CEO Mark Mallon on Q2 2021 Results - Earnings Call Transcript
02:54pm, Friday, 06'th Aug 2021
NeoGenomics, Inc. (NEO) CEO Mark Mallon on Q2 2021 Results - Earnings Call Transcript
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
12:16pm, Friday, 06'th Aug 2021
NeoGenomics (NEO) delivered earnings and revenue surprises of 80.00% and 1.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: NeoGenomics Q2 Earnings
07:51am, Friday, 06'th Aug 2021
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 75.00% year over year to ($0.01), which beat the estimate of ($0.0
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
07:00am, Friday, 06'th Aug 2021
Second-Quarter 2021 Results and Highlights: Consolidated revenue increased 40% to $122 million Clinical Services revenue increased 37% to $101 million Pharma Services revenue increased 55% to $20 mill
Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline
04:43pm, Friday, 30'th Jul 2021
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: NeoGenomics (NEO)
07:38am, Friday, 30'th Jul 2021
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
NeoGenomics: Strong Growth Potential For A Leader In Cancer Diagnostic Testing
12:08am, Friday, 02'nd Jul 2021
NEO operates a broad network of cancer-focused testing centers in the U.S., Europe, and Asia, and is actively seeking new markets to enter. Although the COVID pandemic had an adverse effect on the com
Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading p
Moving Average Crossover Alert: NeoGenomics (NEO)
09:02am, Tuesday, 08'th Jun 2021
NeoGenomics (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences
04:05pm, Thursday, 27'th May 2021
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced
NeoGenomics To Participate In The Bank of America 2021 Health Care Conference
04:15pm, Monday, 10'th May 2021
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announc
3 Top Small-Cap Stocks to Buy Right Now
08:30am, Sunday, 09'th May 2021
These under-the-radar names deserve investors' attention.
NeoGenomics (NEO) CEO Mark Mallon on Q1 2021 Results - Earnings Call Transcript
10:14pm, Wednesday, 05'th May 2021
NeoGenomics (NEO) CEO Mark Mallon on Q1 2021 Results - Earnings Call Transcript
